Longwood Fund
Longwood Fund finances science-based companies that develop novel solutions for medical problems.
Business Model:
Revenue: $11.6M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Longwood Fund Information
Geographic Data
Address: 800 Boylston St
City: Boston
State: MA
Zip: 02199
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$170M
Social
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems
Contact Phone:
+16173512590
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2018 | ArcherDX | Series A | 35M |
| 3/2021 | XyloCor Therapeutics | Series A | 0 |
| 1/2021 | TScan Therapeutics | Series C | 100M |
| 10/2021 | Rectify Pharmaceuticals | Series A | 0 |
| 3/2013 | PTC Therapeutics | Private Equity Round | 60M |
| 6/2017 | Bicycle Therapeutics | Series B | 52M |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 11/2011 | Verastem Oncology | Series C | 20M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 9/2022 | Photys | Series A | 0 |
| 11/2019 | Werewolf Therapeutics | Series A | 0 |
| 2/2019 | Axial Biotherapeutics | Series B | 25M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 2/2021 | ImmuneID | Venture Round | 17M |
| 9/2012 | Vascular Pharmaceuticals | Series A | 16M |
| 7/2019 | TScan Therapeutics | Series B | - |
| 9/2014 | Flex Pharma | Venture Round | 0 |
| 10/2008 | Alnara Pharmaceuticals | Series A | 20M |
| 4/2021 | Renovia | Series C | 0 |
| 12/2022 | Pulmocide | Series C | 0 |
| 9/2015 | Channel Medsystems | Series C | 0 |
| 8/2018 | Renovia | Series B | 32.3M |
| 7/2019 | Pyxis Oncology | Series A | 22M |
| 3/2007 | IlluminOss Medical | Series A | 2.6M |
| 12/2016 | Axial Biotherapeutics | Series A | 19.1M |
| 1/2018 | Recros Medica | Venture Round | 9M |
| 1/2021 | Werewolf Therapeutics | Series B | 0 |
| 4/2022 | Be Biopharma | Series B | 0 |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 10/2013 | Calithera Biosciences | Series D | 35M |
| 11/2010 | Verastem Oncology | Series A | 16M |
| 1/2020 | TScan Therapeutics | Series B | 35M |
| 11/2016 | Axial Biotherapeutics | Series A | 19.5M |
| 6/2020 | Lassen Therapeutics | Series A | 31M |
| 10/2013 | Mitobridge | Series A | 0 |
| 1/2016 | Grail | Series A | 100M |
| 6/2022 | Carbon Biosciences | Series A | 0 |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 9/2014 | Colorescience | Series B | 15M |
| 5/2019 | ArcherDX | Series B | 60M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 12/2019 | ArcherDX | Series C | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 7/2015 | KalVista Pharmaceuticals | Series B | 33M |
| 10/2021 | Axial Biotherapeutics | Series C | 0 |
| 10/2018 | Sitryx Therapeutics | Series A | 30M |
| 5/2021 | Pulmocide | Series C | 0 |
| 3/2017 | Pulmocide | Series B | 30.4M |
| 8/2017 | Channel Medsystems | Series C | 0 |
| 10/2020 | Be Biopharma | Series A | 52M |
| 7/2011 | Verastem Oncology | Series B | 32M |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Carbon Biosciences | Series A | 0 |
| 4/2022 | Be Biopharma | Series B | 0 |
| 10/2021 | Rectify Pharmaceuticals | Series A | 0 |
| 10/2021 | Axial Biotherapeutics | Series C | 0 |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 5/2021 | Pulmocide | Series C | 0 |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 4/2021 | Renovia | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
